Reliance Power shares in focus today after swinging to Rs 125.6 crore profit in Q4 FY25
Despite a marginal 1% dip in revenue to ₹1,978 crore, Reliance Power's operating performance improved sharply. EBITDA surged 1,109% YoY to ₹589.8 crore, up from ₹48.8 crore a year ago. The EBITDA margin also rose significantly to 29.8% from 2.4% in the year-ago period.
Total income for the March quarter stood at ₹2,066 crore. The company also repaid total debt obligations of ₹5,338 crore over the past year, helping it slash its debt-to-equity ratio to 0.88:1 from 1.61:1 in FY24. Net worth stood at ₹16,337 crore as of March 31, 2025.
Operationally, Reliance Power's 3,960 MW Sasan Ultra Mega Power Project reported a plant load factor (PLF) of approximately 87%, while its 1,200 MW Rosa plant in Uttar Pradesh recorded an availability rate of 97%. Notably, the company reported zero bank debt and no defaults.
In a major development, Reliance Nu Suntech, a wholly owned subsidiary, signed a 25-year PPA with SECI to develop Asia's largest solar and battery energy storage system (BESS). The ₹10,000 crore project will pair 930 MW of solar capacity with 465 MW/1860 MWh BESS at a fixed tariff of ₹3.53/unit.
The results were announced after market hours on Friday. Reliance Power shares closed at ₹38.65, up 0.94% on the BSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
an hour ago
- Axios
Conservationists bring public lands podcast tour to Utah
A coalition of environmental organizations is calling attention to what it describes as attacks on public lands, with a tour through the West that arrives in Utah this week. Why it matters: From wildfires to proposed land sales, Utah's wild places have faced new threats this year amid cuts by the Trump administration and a Republican-led Congress. Driving the news: The Center for Western Priorities is taping a podcast live at Fisher Brewing Company, from 6-9pm Thursday, to discuss the fallout from staff and funding cuts to land management agencies. The big picture: Public lands advocates are celebrating the rejection of Sen. Mike Lee's (R-Utah) controversial proposal to sell off up to 3.3 million acres of public land in Western states. Catch up quick: The National Park Service has lost nearly a quarter of its permanent employees since January, according to a July analysis by the National Parks Conservation Association. Glen Canyon National Recreation Area lost conservation specialists and Arches National Park suspended access to one of its most popular hikes in the aftermath of staffing turmoil this spring. At Zion, the Washington Post reported some bathrooms have been replaced with portable toilets and a ranger said some repairs and improvements were being delayed. Zoom out: In Yosemite, scientists were reassigned to bathroom detail and campgrounds were closed in Colorado's Curecanti National Recreation Area. Meanwhile, Congressional Republicans have proposed defunding the management of about half of Grand Staircase-Escalante National Monument. The NPS did not immediately respond to Axios' query Tuesday afternoon. Follow the money: Small businesses in Utah's outdoor industry areas also are strained by President Trump's tariffs and guides are wary of upgrading gear amid projected international tourism losses, Utah Business reported last week.
Business Upturn
an hour ago
- Business Upturn
Prostarm Info bags 150 MW/300 MWh battery storage order from KPTCL
Prostarm Info Systems Limited has been declared the L-1 bidder by Karnataka Power Transmission Corporation Limited (KPTCL) for a landmark energy storage project. The company will set up a 150 MW/300 MWh standalone Battery Energy Storage System (BESS) at the 400kV Doni Substation in Gadag District, Karnataka, operating at 220kV voltage level. The project, awarded under the Tariff Based Competitive Bidding (TBCB) mode, will be executed on a Build-Own-Operate (BOO) basis for 12 years. Prostarm Info Systems will receive a rental of Rs. 2.54 lakh per MW per month, amounting to an annual rental of Rs. 45.72 crore for the entire 150 MW/300 MWh system. Additionally, the project includes Viability Gap Funding (VGF) of Rs. 27 lakh per MWh or 30% of the capital cost for the BESS, whichever is lower. This order marks a significant milestone for Prostarm Info Systems, reinforcing its position in India's renewable energy and energy storage sector. The project is entirely domestic, and there are no related party concerns or promoter interests involved in the award. With this strategic contract, Prostarm Info Systems is poised to contribute significantly to Karnataka's energy infrastructure while advancing sustainable energy solutions. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
8 hours ago
- Business Upturn
Lupin launches Bosentan Tablets for Oral Suspension in US with 180-day exclusivity
By Aditya Bhagchandani Published on August 20, 2025, 10:16 IST Shares of Lupin Ltd. will be in focus on Wednesday, August 20, after the company announced the launch of Bosentan Tablets for Oral Suspension, 32 mg, in the United States. The launch, made in partnership with NATCO Pharma, comes with the advantage of 180-day first-to-file generic exclusivity, a significant opportunity in the niche space of pulmonary arterial hypertension (PAH) treatment. The government filing confirmed that Lupin's alliance partner NATCO Pharma received U.S. FDA approval for its Abbreviated New Drug Application (ANDA). Bosentan is indicated for the treatment of PAH in pediatric patients aged three years and above with idiopathic or congenital PAH, aiming to improve pulmonary vascular resistance and exercise ability. The drug is bioequivalent to Actelion Pharmaceuticals' Tracleer® Tablets for Oral Suspension, which had estimated annual U.S. sales of around USD 10 million as of June 2025. Lupin, a major player in generics and specialty formulations, continues to strengthen its U.S. portfolio with this launch. The company has a strong footprint across therapy areas, including respiratory, cardiovascular, anti-diabetic, and women's health, and operates 15 manufacturing sites and seven research centers globally. With the exclusivity window, Lupin and NATCO are positioned to capture market share in the PAH treatment segment before competition intensifies. Disclaimer: This article is for informational purposes only and should not be considered investment advice. Please consult a financial advisor before making any investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
